Comment on ‘Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors'

@inproceedings{Singhera2013CommentO,
  title={Comment on ‘Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors'},
  author={Mausam Singhera and Robert A Huddart},
  booktitle={British Journal of Cancer},
  year={2013}
}
Willemse et al (2013) recently reported their results regarding prevalence of metabolic syndrome and risk of cardiovascular disease (CVD) in survivors of testicular cancer who were treated with chemotherapy. This topic has particular relevance as cure rates are increasing across all cancer types due to increase in uptake of screening, better imaging modalities and effective treatments. However, we have certain reservations regarding the data presented and the conclusions drawn by the authors… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy - treated testicular germ cell tumour survivors

  • PM Willemse, J Burggraaf, +6 authors S Osanto
  • Br J Cancer
  • 2013
Highly Influential
3 Excerpts

The metabolic syndrome and disturbances in hormone

  • JA Gietema
  • 2005
Highly Influential
3 Excerpts

Early development of the metabolic syndrome after chemotherapy for testicular cancer

  • EC de Haas, R Altena, +10 authors JA Gietema
  • Ann Oncol
  • 2013
1 Excerpt

Evidence - based pragmatic guidelines for the follow - up of testicular cancer : optimising the detection of relapse

  • NJ vanAs, DC Gilbert, +5 authors RA Huddart
  • Br J Cancer
  • 2008

Evidence-based pragmatic guidelines

  • DP, A Horwich, RA Huddart
  • 2008

Similar Papers

Loading similar papers…